- Home
- KZIA vs NYXH Comparison
KZIA vs NYXH Comparison
Compare KZIA & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KZIA | NYXH |
|---|---|---|
| Founded | 1994 | 2009 |
| Country | Australia | Belgium |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.7M | 137.5M |
| IPO Year | 2002 | 2021 |
Fundamental Metrics
Financial Performance| Metric | KZIA | NYXH |
|---|---|---|
| Price | $8.06 | $1.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $28.33 | $4.20 |
| AVG Volume (30 Days) | ★ 245.6K | 151.4K |
| Earning Date | 11-06-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $275.91 |
| Revenue Next Year | N/A | $93.27 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.86 | $1.26 |
| 52 Week High | $17.40 | $6.20 |
Technical Indicators
Market Signals| Indicator | KZIA | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 27.25 | 40.58 |
| Support Level | $5.15 | $1.28 |
| Resistance Level | $8.18 | $1.69 |
| Average True Range (ATR) | 0.58 | 0.07 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 3.54 | 7.50 |
Price Performance
Historical ComparisonAbout KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.